24.4 C
Vientiane
Thursday, August 7, 2025
spot_img
Home Blog Page 74

H2G Green Limited’s GEIH and A*STAR Sign Agreement to Commercialise Biomass-to-Hard Carbon Technology for Sodium-Ion Batteries

As H2G innovates in novel hydrogen production technologies, the biochar byproducts of its process will be refined and commercialised under the agreement.

SINGAPORE, July 30, 2025 /PRNewswire/ — H2G Green Limited (SGX:5AI) (“H2G” or the “Company“, together with its subsidiaries, collectively the “Group“), a leader in sustainable energy solutions, and its subsidiary Green Energy Investment Holding Private Limited (“GEIH“) today announced a licence agreement with Singapore’s Agency for Science, Technology and Research (“A*STAR“).

GEIH is an innovator in sustainable hydrogen with proprietary technologies that repurposes and transforms waste biomass into green hydrogen, as well as biochar and other high-value, sustainable materials. GEIH will commercialise a proprietary treatment process by A*STAR Institute of Materials Research and Engineering (A*STAR IMRE) to purify biochar, a by-product, into high-value hard carbon material for market use. Hard carbon materials are primarily used as anodes for batteries such as sodium-ion and lithium-ion batteries, due to their unique properties. They are also found in applications for water and air purifications as well as conductive additive in paints and coatings.

GEIH’s proprietary technology transforms waste biomass into green hydrogen, as well as biochar and other high-value, sustainable materials.
GEIH’s proprietary technology transforms waste biomass into green hydrogen, as well as biochar and other high-value, sustainable materials.

Following execution of the licence agreement, GEIH and A*STAR will begin the next phase of scaling up to accelerate the commercialisation pathway of the biochar purification process, focusing on producing hard carbon as anodes for use in sodium-ion batteries.

Mr. Sydney Kwan, CEO of GEIH, remarked: “We are deeply grateful to A*STAR for their ongoing collaboration and support. Our joint efforts are transforming the nation into a hub for sustainable technologies and green energy.”

An earlier exploratory phase found that the hard carbon GEIH produces tends to be superior to existing commercial materials due to a high graphite content, which makes the material favourable for anodes in sodium-ion batteries. These have possible applications for grid-scale energy storage, electric vehicles, and consumer electronics. The abundance of sodium makes sodium-ion batteries a more sustainable alternative to lithium-ion batteries.

GEIH’s technologies make it especially suited to this endeavour. The Company’s proprietary high-temperature thermochemical process turns any type of biomass without silica into hydrogen, biochar, bio-oil (for sustainable aviation fuel), and wood vinegar. The entire process incorporates circularity of materials as a guiding principle, and production of biochar results from incorporating carbon sequestration. The output materials power sectors as diverse as data centres, wafer fabrication, construction, agriculture, food manufacturing, laundry services, and central kitchens.

Mr. Pek Hak Bin, CEO of H2G, added: “Hydrogen is the energy of the future and a core part of Singapore’s low-carbon energy strategy. H2G is expanding possibilities for Singapore and beyond by pioneering a novel hydrogen production process that is cost-effective, less carbon intensive than electrolysis, and repurposes waste into sustainable materials. These power sustainable industries, as our hard carbon anode materials for sodium-ion batteries will empower a broader range of industries to reduce their environmental impact. In this way, H2G creates win-win-win sustainability solutions to multiple problems across industries.”

About H2G Green Limited

H2G focuses on delivering sustainable energy solutions through its two subsidiaries: GasHubUnited Utility Private Limited (“GasHub“) for LNG and GEIH for hydrogen, biochar, and other high-value, sustainable materials. In Singapore, the Company is working towards solving the energy trilemma — advancing cost competitiveness of sustainable energies, expanding energy security, and transitioning to net zero. Beyond Singapore, the Company is powering Southeast Asia’s transition towards cleaner, sustainable energy solutions. H2G stands out for deep engineering, energy, and sustainability expertise and an unwavering commitment to safety.

For more information about H2G and GEIH, please visit: https://h2g.green.

Media & Investor Contacts:

Tel: (+65) 6741 3939
Email: h2g@h2g.green

FranklinWH Approved by Brighte, Advancing Home Battery Storage Accessibility for Australian Homes

SYDNEY, July 30, 2025 /PRNewswire/ — FranklinWH Australia Pty Ltd. (FranklinWH Australia), a leading global provider of home energy management and storage systems, is officially approved by Brighte to offer battery storage finance. This partnership will give numerous Australian homeowners easy and flexible access to reliable energy solutions.

There are two key financing paths through Brighte:

  • A 0% Interest Payment Plan, with no interest charged over the loan term, perfect for budget-conscious homeowners.
  • A Green Loan with competitive fixed interest rates, offering longer repayment terms and broader eligibility.

Both financing options are available for the purchase and installation of FranklinWH aPower batteries through Brighte-accredited installers. Homeowners can borrow up to $55,000, repay over terms of up to 10 years.

“This approval is a big win for both installers and homeowners,” said Steve Ruskin, GM of FranklinWH Australia/NZ. “It removes the upfront cost barrier by giving homeowners real financial flexibility.”

FranklinWH’s flagship home battery, the aPower X, offers a 13.6 kWh capacity with a 12-year warranty and can scale with multiple units to meet whole-home energy demands. The Brighte approval means homeowners don’t have to delay a home battery addition to their solar systems due to high upfront costs.

The partnership also unlocks advantages for FranklinWH’s installer network. Installers can now offer point-of-sale financing backed by Brighte’s financing platform, which helps accelerate deal closure, reduce drop-off rates, and improve customer satisfaction.

Both companies see this move as timely, given rising electricity prices, increased demand for backup power, and more government incentives for electric alternatives. FranklinWH and Brighte are confident the collaboration will help more Australians transition to more intelligent and reliable home energy.

About FranklinWH

FranklinWH is a market-oriented, research-driven company focused on next-generation residential energy management and storage solutions. Headquartered in the San Francisco Bay Area, FranklinWH’s team has decades of experience in energy systems, from design, through manufacturing, sales, installation, and service. 

About Brighte

Brighte, Australia’s leading affordability and accessibility platform for consumer energy resources (CER) helps homeowners upgrade to cleaner, smarter technology. Since 2015, Brighte has supported over 260,000 Australian households and funded more than A$2 billion in sustainable home improvements, including solar, batteries, and electrification systems.

Media Contacts:

FranklinWH: media@franklinwh.com

All applications are subject to Brighte’s credit approval criteria. Fees, Terms and Conditions apply. Australian Credit Licence Number 508217. Visit brighte.com.au for more information.

Nota AI Secures Preliminary Fast-Track KOSDAQ Approval, Highlighting Global Success in AI Optimization

  • Approval Underscores Technological Excellence and Commercial Viability amid Challenging Market Conditions
  • Positioned to Become the First AI Optimization Company on KOSDAQ, Accelerating Global Expansion Efforts

SEOUL, South Korea, July 30, 2025 /PRNewswire/ — Nota AI, a leading provider of AI model optimization technology, today announced that it has received preliminary approval for a KOSDAQ listing, granted by the Korea Exchange. The company secured the approval just two months after filing, following its “A•A” rating in Korea’s official technology evaluation process last December. Nota AI aims to complete its IPO in the second half of 2025, with Mirae Asset Securities serving as the lead underwriter.

Nota AI Secures Preliminary Fast-Track KOSDAQ Approval, Highlighting Global Success in AI Optimization
Nota AI Secures Preliminary Fast-Track KOSDAQ Approval, Highlighting Global Success in AI Optimization

This swift approval is particularly noteworthy given the heightened regulatory scrutiny and sharp decline in IPO approvals during the first half of 2025. Nota AI’s success highlights its ability to meet increasingly stringent standards for both technological innovation and commercial viability. A key factor in the approval was the company’s proven track record of overseas customer wins and consistent revenue growth.

At the core of Nota AI’s value proposition is its proprietary platform, NetsPresso®—an end-to-end solution for developing and deploying lightweight, efficient AI models. The company has already commercialized this technology through collaborations with global semiconductor leaders, including NVIDIA, Samsung Electronics, Arm, Qualcomm, Sony, and Renesas.

Building on this foundation, Nota AI has expanded into key verticals—such as industrial safety, surveillance, and intelligent transportation systems (ITS)—through strategic contracts and successful commercial deployments. Among the solutions supporting these initiatives is the Nota Vision Agent (NVA), an advanced video monitoring system powered by the company’s proprietary Vision Language Model (VLM).

Notably, in April 2025, Nota AI signed a supply agreement with Dubai’s Roads and Transport Authority (RTA), becoming the first Korean company to deliver a generative AI solution to a government agency in the Middle East.

“This fast-track approval, amid today’s rigorous IPO environment, demonstrates that Nota AI is more than just a promising startup—we’re a globally recognized company with proven technology and business impact,” said Myungsu Chae, CEO of Nota AI. “Through this IPO, we aim to set a new global standard in AI optimization and accelerate the real-world adoption of AI across industries.”

Nota AI began its global expansion by establishing overseas offices in Germany and the United States. Since then, the company has rapidly scaled operations in regions including the Middle East, Japan, and Southeast Asia. With its technology-driven business model reaching maturity, Nota AI has grown its revenue nearly tenfold over the past five years. The company projects year-over-year growth exceeding 72% in 2025. IPO proceeds will be used to advance R&D and accelerate global business expansion.

Telix H1 2025 Results: Investor Webcast Notification

MELBOURNE, Australia and INDIANAPOLIS, July 30, 2025 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today advises that it will release its financial results for the half-year ended 30 June 2025 on Thursday 21 August 2025.

An investor webcast and conference call will be held at 9.30am AEST on Thursday 21 August 2025 (7.30pm EDT Wednesday 20 August 2025).   

Participants can register for the webcast at the following link: https://edge.media-server.com/mmc/p/x4gytx8w/

Participants can register for the teleconference here: https://s1.c-conf.com/diamondpass/10049152-x745re.html

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedInX and Facebook

Telix Investor Relations
Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com

Telix Investor Relations (U.S.) 
Annie Kasparian 
Telix Pharmaceuticals Limited 
Director Investor Relations and Corporate Communications 
Email: annie.kasparian@telixpharma.com 

This announcement has been authorized for release by Telix Pharmaceuticals Limited’s Company Secretary, Genevieve Ryan.  

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements. 

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2025 Telix Pharmaceuticals Limited. All rights reserved.

2025 AI Expo Opens in Suzhou, Highlighting Innovation in AI Industry Development

SUZHOU, China, July 30, 2025 /PRNewswire/ — The 7th AI Product & Application Expo (“2025 AI Expo”), organized by the New Generation AI Industry Technology Innovation Strategic Alliance (AITISA), opened today in Suzhou. This year’s event focused on high-impact themes including embodied intelligence, digital transformation, and industrial AI. A full slate of exhibitions, forums, and matchmaking sessions was held to foster industry collaboration, accelerate technical breakthroughs, and enable cross-sector innovation—shaping conversations around the trajectory of AI and the evolving contours of the industry.


At the opening ceremony, three industry-defining reports were released: the Annual Report on New Generation AI Development (2024–2025), the China Urban AI Development Index Report (2024–2025), and the AI Industry Investment Trends and Development Report. These publications provide key benchmarks for tracking the progress of China’s AI ecosystem. The Expo also hosted a recognition ceremony for the 2025 AI Technology Leadership Talent Settlement Projects and presented awards for the 3rd AI Product & Application Innovation and Entrepreneurship Competition and the 2nd Zu Chongzhi Award for Frontier Innovation in Artificial Intelligence.

More than 20 high-profile product launches were unveiled at the new release showcase. The Expo also introduced a new “Black Tech” experience zone, where over 20 companies presented more than 200 cutting-edge technologies in an immersive demonstration space. The zone included on-site purchasing options, linking forward-looking innovation with real-world consumer engagement. To strengthen regional integration, the event expanded collaboration with Shanghai’s World Artificial Intelligence Conference (WAIC), promoting talent exchange, scenario-based deployment, and shared resource strategies across the Yangtze River Delta—reinforcing Suzhou’s role as a national model for AI+ application deployment.

Suzhou Industrial Park, the city’s engine of AI innovation, has played a leading role in advancing AI and digital industries since 2017. From the ground up, it has built an ecosystem for AI R&D, pilot applications, and industrial clustering. In recent years, the park has stepped up its “AI+” strategy, targeting next-wave technologies such as foundation models and embodied AI. It now hosts multiple national research centers and innovation platforms, and has attracted leading AI companies from China and abroad. As AI becomes more deeply embedded in the real economy, the park is driving the emergence of an AI-powered industrial cluster valued at over 100 billion yuan.

Vexev and U.S. Renal Care Complete Enrollment in Groundbreaking Trial Evaluating Use of Robotic Ultrasound Scanning for AV Fistula Mapping in Dialysis Clinics

  • CANSCAN study enrolled 120 patients with chronic kidney disease using the investigational, semi-autonomous VxWave™ Ultrasound Imaging System
  • The VxWave Ultrasound Imaging System potentially provides important insights into vascular access, to possibly enable earlier creation and use of AV fistula
  • Results to be presented at American Society of Nephrology (ASN) Annual Meeting in November

SYDNEY and SAN ANTONIO, July 30, 2025 /PRNewswire/ — Vexev, an Australian-based medical device company advancing next-generation vascular imaging, and U.S. Renal Care, a leading provider of in-center and home dialysis in the United States, today announced the successful completion of enrollment in the CANSCAN clinical trial (NCT06691672). The first-of-its-kind, multi-center feasibility study enrolled 120 patients with chronic kidney disease to evaluate the use of semi-autonomous ultrasound scanning utilizing the VxWave Ultrasound Imaging System for arteriovenous (AV) fistula mapping in dialysis clinics.

The Vexev and U.S. Renal Care teams successfully completed enrollment in the CANSCAN trial. The study is evaluating the use of semi-autonomous ultrasound scanning with the VxWave Ultrasound Imaging System for AV fistula mapping in dialysis clinics.
The Vexev and U.S. Renal Care teams successfully completed enrollment in the CANSCAN trial. The study is evaluating the use of semi-autonomous ultrasound scanning with the VxWave Ultrasound Imaging System for AV fistula mapping in dialysis clinics.

“The VxWave ultrasound system may remove one of the biggest hurdles in the creation of vascular access. Patients could have vascular mapping conducted in their dialysis facility, enabling a more efficient way to obtain a permanent vascular access point,” commented Varshi Broumand, MD, MHA, FACP, FASN, Interventional Nephrologist at South Texas Renal Care Group and CANSCAN Study Principal Investigator. “Performing the ultrasound scans during the clinic visit would make AV fistula mapping more convenient and timely and potentially avoid sending patients to additional imaging appointments.”

An AV fistula is a connection made between an artery and a vein, typically in the arm, to create an access point for patients requiring dialysis. This allows blood to flow quickly and easily during treatment, which helps the body remove toxins more effectively. The VxWave Ultrasound Imaging System is a robotic tomographic ultrasound system specifically designed for upper limb vascular imaging – integrating advanced robotics, machine learning and ultrasound signal processing to create a 3D vascular model and detailed report that potentially provides insights into vascular access points – all at the point of care.

“Validating this concept is the first step toward a future where intelligent machines can perform high-precision medical imaging without a human hand on the probe. The potential for a robotic system guided by AI, delivering real clinical value – it’s not science fiction anymore,” said Shannon Thomas, MD, Chief Medical Officer, Vexev. “The real excitement begins when this can change lives, not just lab results. This is a huge step forward in our mission to improve the lives of millions of people worldwide living with end-stage kidney disease.”

“U.S. Renal Care is committed to delivering innovative treatments that address the most critical needs for people living with kidney disease,” said Geoffrey A. Block, MD, FASN, Associate Chief Medical Officer & Senior Vice President, Clinical Research & Medical Affairs, U.S. Renal Care. “The CANSCAN trial of the VxWave Ultrasound Imaging System opens the possibility of integrating semi-autonomous ultrasound imaging into our workflow and improving patient outcomes, by allowing patients to receive life-saving permanent vascular access placed in the optimal location, as quickly as possible.”

About Vexev
Vexev is an Australian med‑tech startup founded in 2018 by Drs. John Carroll and Eamonn ColleyUniversity of New South Wales (UNSW) PhD graduates in vascular fluid dynamics and computational imaging. Vexev is on a mission to improve lives by developing the next generation of vascular imaging solutions. Visit Vexev.com to learn more.

About U.S. Renal Care
U.S. Renal Care, the fastest-growing dialysis provider in the nation, partners with nephrologists across 32 states in the U.S. to care for more than 36,000 people living with kidney disease. Since 2000, U.S. Renal Care has been a leader in clinical quality, innovation, and operational excellence – delivering the best experience and outcomes for our patients. Visit USRenalCare.com to learn more.

Photo – https://laotiantimes.com/wp-content/uploads/2025/07/vexev_usrenal_canscan.jpg
Logo – https://laotiantimes.com/wp-content/uploads/2025/07/vexev_logo.jpg

Pendo Opens Australia Data Center to Serve Growing APAC Customer Base

The sixth global data center expands data security and access compliance to global customers.

RALEIGH, N.C. and SYDNEY, July 29, 2025 /PRNewswire/ — Pendo, the world’s first software experience management platform, has opened a data center in Australia, strengthening its data security and local compliance with general privacy law and sector-specific mandates in the region. The new onshore facility benefits Pendo’s more than 120 regional customers, many of whom work in regulated industries and prioritize local data residency.

“We take our customer data responsibilities seriously, so ensuring we can host the data in Australia is critical,” said Aydin Mustafa, general manager for product development at HUB24, a leading wealth management platform. “We’re delighted to be partnering with Pendo, which enables us to deeply understand our customers and how they are using our solutions.”

Global companies value relationships with vendors like Pendo that can comply with industry and regulatory standards for data privacy and security. Pendo now operates six global data centers, which include sites in the United States, the European Union, and Japan, and is compliant with SOC2, GDPR, TX-RAMP, and HIPAA.

Pendo opened its Sydney office in 2020 and has grown its Asia-Pacific team by 40 percent in the past year to support rapid regional expansion. International growth comes as Pendo accelerates its investment in AI innovation, announcing the recent acquisition of the no-code predictive analytics platform Forwrd.ai and a series of product releases that help companies measure the performance of AI agents, improve user onboarding, cut support costs, increase upsell revenue, and drive team productivity.

“Having a customer-first mindset means removing barriers for customers, like data storage compliance, so they can focus on creating software that users love,” said APAC Area Vice President at Pendo, Benjamin Weldon. “I believe this region will be a global hub for digital innovation, where product-led strategies drive growth and meaningful customer engagement.”

About Pendo

At Pendo, we’re on a mission to improve the world’s experience with software. Thousands of global companies use Pendo to provide better software experiences for 900 million people every month. Pendo improves business outcomes by enabling non-engineers to analyze, assess, and act on software issues. Our integrated Software Experience Management (SXM) platform manages the entire enterprise software asset: Customer- and employee-facing applications; desktop and mobile platforms; and SaaS, AI and Agentic software. Find out more at pendo.com

FROM THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE 2025: ALZHEIMER’S ASSOCIATION RELEASES ITS FIRST CLINICAL PRACTICE GUIDELINE FOR BLOOD-BASED BIOMARKER TESTS

Key Takeaways

  • At AAIC 2025, the Alzheimer’s Association released the first in a series of clinical practice guidelines for the diagnosis, treatment and care of Alzheimer’s and all other dementia.
  • The guideline focuses on the use of blood-based biomarker tests by specialists to assess levels of Alzheimer’s disease pathology in people with cognitive impairment.
  • The Alzheimer’s Association provides evidence-based resources to help clinicians identify the disease early and ensure patients receive the right treatment as quickly as possible.
  • These and other planned guidelines are part of ALZPro, the Alzheimer’s Association’s centralized hub for resources, support and information for dementia professionals.

TORONTO, July 30, 2025 /PRNewswire/ — In a landmark step toward transforming Alzheimer’s disease diagnosis in specialty care, the Alzheimer’s Association today released its first clinical practice guideline (CPG) on the use of blood-based biomarker (BBM) tests. The guideline is being reported at the Alzheimer’s Association International Conference® 2025 (AAIC®) in Toronto and online, and published in Alzheimer’s & Dementia®: The Journal of the Alzheimer’s Association.

The CPG provides clear evidence-based, brand-agnostic recommendations to support more accurate and accessible diagnosis of Alzheimer’s using blood-based biomarker tests. The recommendations are linked to a systematic review using a robust and transparent methodology, and will be updated regularly as evidence evolves.

“This is a pivotal moment in Alzheimer’s care,” said Maria C. Carrillo, Ph.D., Alzheimer’s Association chief science officer and medical affairs lead, and a co-author of the guideline. “For the first time, we have a rigorously evidence-based guideline that empowers clinicians to use blood biomarker tests confidently and consistently. Adoption of these recommendations will lead to quicker, more accessible, more accurate diagnoses — and better outcomes for individuals and families affected by Alzheimer’s.”

The recommendations in the new CPG — both of which apply only to patients with cognitive impairment being seen in specialized care for memory disorders — are:

  • BBM tests with ≥90% sensitivity and ≥75% specificity can be used as a triaging test, in which a negative result rules out Alzheimer’s pathology with high probability. A positive result should also be confirmed with another method, such as a cerebral spinal fluid (CSF) or amyloid positron emission tomography (PET) test.
  • BBM tests with ≥90% for both sensitivity and specificity can serve as a substitute for PET amyloid imaging or CSF Alzheimer’s biomarker testing.

The guideline cautions that there is significant variability in diagnostic test accuracy and many commercially available BBM tests do not meet these thresholds.

“Not all BBM tests have been validated to the same standard or tested broadly across patient populations and clinical settings, yet patients and clinicians may assume these tests are interchangeable,” said Rebecca M. Edelmayer, Ph.D., Alzheimer’s Association vice president of scientific engagement and a co-author of the guideline. “This guideline helps clinicians apply these tools responsibly, avoid overuse or inappropriate use, and ensure that patients have access to the latest scientific advancements.”

Compared to standard-of-care PET imaging and CSF tests, blood-based biomarkers are typically less costly, more accessible and more acceptable to patients. The guideline emphasizes that BBM tests do not substitute for a comprehensive clinical evaluation by a health care professional, and should be ordered and interpreted by a health care professional in the context of clinical care.

This is the first evidence-based guideline using Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology in the Alzheimer’s space. The use of GRADE ensures a transparent, structured and evidence-based process for evaluating the certainty of evidence and formulating recommendations. This strengthens the credibility and reproducibility of the guideline and allows for explicit linkage between evidence and recommendations.

This guideline’s primary audience includes specialists involved in the diagnostic evaluation of cognitive impairment in specialized care settings. A specialist is defined as a health care provider, typically in neurology, psychiatry or geriatrics, who cares for adults with cognitive impairment or dementia. It also applies to primary care providers, nurse practitioners and physician assistants in specialized care settings.

A panel of 11 clinicians convened by the Alzheimer’s Association — including clinical neurologists, geriatricians, nurse practitioners, physician assistants and subject-matter experts — conducted a systematic review and formulated evidence-based recommendations for using blood-based biomarkers in individuals with objective cognitive impairment, including those with mild cognitive impairment (MCI) or dementia. Final recommendations were informed by public comments and input from the Association’s National Early-Stage Advisory Group, which includes people living with early-stage Alzheimer’s.

For this initial iteration of the guideline, the BBMs included plasma phosphorylated-tau (p-tau) and amyloid-beta (Aβ) tests measuring the following analytes: p-tau217, ratio of p-tau217 to non-p-tau217 ×100 (%p-tau217), p-tau181, p-tau231, and ratio of Aβ42 to Aβ40. The various BBM tests measure abnormal forms of either amyloid beta or tau protein, the two biomarkers associated with Alzheimer’s disease. Forty-nine (49) observational studies were reviewed and 31 BBM tests were evaluated.

The panel determined that endorsing specific tests was premature, opting for a brand-agnostic, performance-based approach that blinded panel members to the tests they were evaluating to minimize bias. This ensures the guideline’s credibility, durability and actionability. According to the panel: “Ranking or endorsing specific tests is premature at this time. Instead, test accuracy data and accuracy judgments reported in this guideline are meant to serve as a resource for clinicians … to aid them in choosing which test(s) to order.”

The panel formulated two recommendations and one Good Practice Statement for the use of BBM tests in the diagnostic workup of patients with objective cognitive impairment being seen in specialized care.

  • Recommendation 1 — In patients with objective cognitive impairment presenting for specialized memory-care, the panel suggests using a high-sensitivity BBM test as a triaging test in the diagnostic workup of Alzheimer’s disease.
  • Recommendation 2 — In patients with objective cognitive impairment presenting for specialized memory care, the panel suggests using a high-sensitivity and high-specificity BBM test as a confirmatory test in the diagnostic workup of Alzheimer’s disease.
  • Good Practice Statement — A BBM test should not be obtained before a comprehensive clinical evaluation by a health care professional, and test results should always be interpreted within the clinical context. The panel urges clinicians to consider the pre-test probability of Alzheimer’s disease pathology for each patient when deciding whether or not to use a BBM test.

This CPG is part of ALZPro™, the Alzheimer’s Association’s comprehensive hub of resources to promote best practices, empowering health professionals across disciplines to reduce risk, advance early detection, improve care and expand equitable access for all communities. ALZPro unites care resources, relevant scientific findings, clinical guidelines and insights, continuing education and implementation tools on one platform.

Upcoming clinical practice guidelines will address cognitive assessment tools (Fall 2025), clinical implementation of staging criteria and treatment (2026) and prevention of Alzheimer’s and other dementias (2027). This clinical practice guideline was convened and funded by the Alzheimer’s Association, but the Association was not involved in formulating the clinical questions or recommendations.

About the Alzheimer’s Association International Conference® (AAIC®)
The Alzheimer’s Association International Conference (AAIC) is the world’s largest gathering of researchers from around the world focused on Alzheimer’s and other dementias. As a part of the Alzheimer’s Association’s research program, AAIC serves as a catalyst for generating new knowledge about dementia and fostering a vital, collegial research community.
AAIC 2025 home page: www.alz.org/aaic/  
AAIC 2025 newsroom: www.alz.org/aaic/pressroom.asp
AAIC 2025 hashtag: #AAIC25

About the Alzheimer’s Association®
The Alzheimer’s Association is a worldwide voluntary health organization dedicated to Alzheimer’s care, support and research. Our mission is to lead the way to end Alzheimer’s and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer’s and all other dementia®. Visit alz.org or call 800.272.3900.

Session: Evidence-Based Clinical Practice Guidelines for Detection and Diagnosis of Cognitive Impairment using Blood-based Biomarkers and Cognitive Testing: Two Guideline Initiatives from the Alzheimer’s Association

Proposal ID: 108894
Oral Presentation: Tuesday, July 29, 2025: 2:00 P.M.-3:30 P.M. EDT (3-21-DEV)

Clinical practice guideline for blood-based biomarkers in the diagnostic workup of Alzheimer’s disease within specialized care settings: A report from the Alzheimer’s Association

Background: In recent years, blood-based biomarkers (BBMs) have transformed the diagnostic landscape of Alzheimer’s disease (AD), with some now approaching readiness for clinical implementation. This progress aligns with the growing importance of accurate early diagnostics and availability of anti-Aβ therapies for the treatment of early symptomatic AD, reinforcing the need for more rapid and early diagnostic capabilities. To address this need, the Alzheimer’s Association convened a multidisciplinary panel of clinical experts, subject-matter specialists, and guideline methodologists to conduct a systematic review and develop evidence-based recommendations for the use of BBMs in the diagnostic evaluation of AD. The scope of this guideline is focused on individuals with cognitive impairment – either MCI or dementia – who are undergoing diagnostic assessment in secondary or tertiary care settings.

Method: The panel conducted a systematic review to assess BBMs’ diagnostic test accuracy in detecting amyloid pathology for triaging (≥90% sensitivity, ≥75% specificity) and confirmatory (≥90% sensitivity and specificity) diagnostic workup. The BBMs of interest included plasma p-tau and Aβ tests measuring the following analytes: p-tau217, %p-tau217, p-tau181, p-tau231, and Aβ42/Aβ40 ratio. The reference standard tests included CSF, amyloid PET, or neuropathology examination. The panel applied the GRADE approach to assess the certainty of the evidence and the GRADE Evidence-to-Decision Framework to develop its recommendations.

Result: Across 49 observational studies meeting eligibility criteria, 31 different BBM tests were evaluated. Using predefined decision thresholds, the panel determined whether each test has 1) sufficient diagnostic test accuracy to be used as a triaging test where a positive test is to be confirmed by PET or CSF, 2) sufficient diagnostic test accuracy as a confirmatory test to replace PET or CSF, or 3) insufficient diagnostic test accuracy to recommend current use in clinical practice. Recommendations will be provided in case any BBMs met a priori DTA thresholds.

Conclusion: BBMs can improve early AD diagnosis and expand access to disease-modifying therapies. Evidence-based guidelines are key to standardizing their use and will be updated as new evidence and applications emerge.